Loading filters...
50 results(scroll for more)
Generalearly2026
Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study.
Zou S et al. Pancreas. 2026
Generaladvanced2026
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Yasuda S et al. Ann Surg. 2026
Generaladvanced2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Wainberg ZA et al. Nat Med. 2026
Generaladvanced2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
Perez KJ et al. Nat Cancer. 2026
Generaladvanced2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.
Kan T et al. Int J Cancer. 2026
GeneralAll Stages2026
Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.
Hong J et al. Cancer Discov. 2026
Generalearly2026
Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
Takeda T et al. J Hepatobiliary Pancreat Sci. 2026
GeneralAll Stages2026
New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer.
Springfeld C et al. Br J Cancer. 2026
Generalearly2026
Inframesocolic Artery-First Approach with SMA Divestment to Confirm Resectability in Minimally Invasive Modified Appleby Procedure.
Blanco N et al. Ann Surg Oncol. 2026
Generaladvanced2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).
Chiang NJ et al. Eur J Cancer. 2026
GeneralAll Stages2026
The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients.
Schneider F et al. Eur J Cancer. 2026
Generalearly2026
Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial.
Lambert A et al. Ann Surg. 2026
GeneralAll Stages2026
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial.
Rompen IF et al. Ann Surg. 2026
Generalearly2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.
Willems RAL et al. J Clin Oncol. 2026
BRCA/HRDadvanced2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Park W et al. Nat Med. 2026
Generaladvanced2026
Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study).
Goetze TO et al. Int J Cancer. 2026
Generalearly2026
Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction.
Palen A et al. Ann Surg Oncol. 2026
Generaladvanced2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.
Macarulla T et al. ESMO Open. 2026
MSI-H/dMMRAll Stages2026
Minimal Residual Disease Assessment Through ctDNA Facilitates Tailored Immunotherapy in MSI-High, NTRK1-Fusion Pancreatic Adenocarcinoma.
Rohlfing S et al. Oncologist. 2026
Generaladvanced2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
Mahalingam D et al. Nat Med. 2026
GeneralAll Stages2026
Tumor microenvironment gene engineering with LOAd703 in patients with solid malignancies: LOKON002 phase I/IIb clinical trial.
Hahn A et al. Clin Cancer Res. 2026
Generalearly2026
Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment.
Lansbergen MF et al. Int J Cancer. 2026
KRAS mutantAll Stages2026
Emerging landscape of KRAS inhibitors in cancer treatment.
Riedl JM et al. Cancer Cell. 2026
KRAS mutantAll Stages2026
Skin health in oncology: evidence-based skin care for cancer patients.
Kaminsky A et al. Oncologist. 2026
Generalearly2026
Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial.
Lee D et al. J Hepatobiliary Pancreat Sci. 2026
Generaladvanced2026
Pancreatic Ductal Adenocarcinoma with ITSN1-ALK Fusion: Sustained Response to Alectinib with 19-Month Progression-Free Survival.
Liu C et al. Oncologist. 2026
Generaladvanced2026
Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab-Paclitaxel for Unresectable Pancreatic Cancer.
Itonaga M et al. J Hepatobiliary Pancreat Sci. 2026
GeneralAll Stages2026
Stapled Wedge Resection of the Portal Vein/Superior Mesenteric Vein During Robotic Pancreaticoduodenectomy: Feasibility and Short-term Outcomes.
Imamura T et al. Ann Surg Oncol. 2026
BRCA/HRDAll Stages2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
Huffman BM et al. Clin Cancer Res. 2026
GeneralAll Stages2026
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.
Alagesan B et al. Clin Cancer Res. 2026
Generalearly2026
A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Suto H et al. Ann Surg Oncol. 2026
Generaladvanced2026
Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial.
Gehrels AM et al. Eur J Cancer. 2026
Generalearly2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancer.
Viniotis AF et al. Oncologist. 2026
Generalearly2026
Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.
Unno M et al. Ann Surg. 2026
Generalearly2026
Class IA Pancreatosplenectomy with Class IA Celiac Axis Resection, SMA Isolation, and Lateral Venous Reconstruction with Peritoneal Patch: A Standardized Technique.
Artaud V et al. Ann Surg Oncol. 2026
Generaladvanced2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.
Hendifar AE et al. J Clin Oncol. 2026
GeneralAll Stages2026
Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.
Henault D et al. Ann Surg. 2026
Generalearly2026
High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.
Fujita K et al. Ann Surg Oncol. 2026
Generaladvanced2026
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial.
Yoo C et al. Ann Surg Oncol. 2026
Generalearly2026
Clinical Significance of an R1 Resection for Pancreatic Ductal Adenocarcinomas Treated by Intensive FOLFIRINOX Induction-Based Chemotherapy and Extended Pancreatectomies.
Addeo P et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy.
Bouchart C et al. Br J Cancer. 2026
BRCA/HRDadvanced2026
Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC).
Kasi A et al. Oncologist. 2026
Generaladvanced2026
Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment.
Debiais M et al. Eur J Cancer. 2026
Generalearly2026
Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Injury and Postoperative Complications.
Tessier F et al. Ann Surg Oncol. 2026
KRAS mutantAll Stages2026
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.
Long SA et al. Cancer Res. 2026
GeneralAll Stages2026
Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer.
Cathomas M et al. Ann Surg Oncol. 2026
Generaladvanced2026
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.
Ni J et al. Clin Cancer Res. 2026
BRCA/HRDAll Stages2026
Precision oncology promise in the management of pancreatic acinar cell carcinoma.
Baskar S et al. Eur J Cancer. 2026
Generalearly2026
Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer.
Ballarò R et al. Cancer Res. 2026
BRCA/HRDadvanced2026
Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma.
Li C et al. Cancer Res. 2026